Satellos Bioscience (MSLE) vs Atrium Therapeutics (RNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Satellos Bioscience is the larger company by market cap ($137.1 million vs $131.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MSLE | RNA |
|---|---|---|
| Share price | $6.46 | $7.67 |
| Market cap | $137.06M | $131.20M |
| 1-day change | -5.56% | -1.92% |
| YTD return | +9.86% | — |
| 1-year return | -5.89% | — |
| 5-year return | -53.95% | — |
| EPS (TTM) | $-1.95 | $-5.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-24.87M | — |
| 52-week high | $13.40 | $16.77 |
| 52-week low | $5.30 | $7.54 |
| Distance from 52-week high | -51.77% | -54.26% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +274.15% | +225.95% |
| Average volume | 46.92K | 259.72K |
| Shares outstanding | 21.22M | 17.11M |
| Employees | 18 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Satellos Bioscience
MSLE stock →Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.
Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees
About Atrium Therapeutics
RNA stock →Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.
Health Care · Biotechnology: Pharmaceutical Preparations
MSLE vs RNA FAQ
Which is bigger, Satellos Bioscience or Atrium Therapeutics?
Satellos Bioscience (MSLE) is larger, with a market capitalization of $137.06M compared with $131.20M for Atrium Therapeutics (RNA).
Are Satellos Bioscience and Atrium Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.